1. Home
  2. RDW vs OCS Comparison

RDW vs OCS Comparison

Compare RDW & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDW
  • OCS
  • Stock Information
  • Founded
  • RDW 2020
  • OCS 2003
  • Country
  • RDW United States
  • OCS Switzerland
  • Employees
  • RDW N/A
  • OCS N/A
  • Industry
  • RDW Military/Government/Technical
  • OCS Biotechnology: Pharmaceutical Preparations
  • Sector
  • RDW Industrials
  • OCS Health Care
  • Exchange
  • RDW Nasdaq
  • OCS Nasdaq
  • Market Cap
  • RDW 800.5M
  • OCS 717.3M
  • IPO Year
  • RDW N/A
  • OCS N/A
  • Fundamental
  • Price
  • RDW $13.93
  • OCS $16.98
  • Analyst Decision
  • RDW Strong Buy
  • OCS Strong Buy
  • Analyst Count
  • RDW 5
  • OCS 5
  • Target Price
  • RDW $10.95
  • OCS $29.20
  • AVG Volume (30 Days)
  • RDW 878.1K
  • OCS 38.1K
  • Earning Date
  • RDW 11-06-2024
  • OCS 11-07-2024
  • Dividend Yield
  • RDW N/A
  • OCS N/A
  • EPS Growth
  • RDW N/A
  • OCS N/A
  • EPS
  • RDW N/A
  • OCS N/A
  • Revenue
  • RDW $298,026,000.00
  • OCS $1,027,571.00
  • Revenue This Year
  • RDW $28.47
  • OCS $6.87
  • Revenue Next Year
  • RDW $18.23
  • OCS $884.16
  • P/E Ratio
  • RDW N/A
  • OCS N/A
  • Revenue Growth
  • RDW 27.35
  • OCS N/A
  • 52 Week Low
  • RDW $2.68
  • OCS $10.11
  • 52 Week High
  • RDW $15.25
  • OCS $18.00
  • Technical
  • Relative Strength Index (RSI)
  • RDW 61.81
  • OCS 61.09
  • Support Level
  • RDW $12.27
  • OCS $15.45
  • Resistance Level
  • RDW $14.09
  • OCS $17.50
  • Average True Range (ATR)
  • RDW 1.25
  • OCS 0.47
  • MACD
  • RDW -0.09
  • OCS 0.09
  • Stochastic Oscillator
  • RDW 84.94
  • OCS 65.57

About RDW Redwire Corporation

Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's Heritage plus Innovation strategy enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Share on Social Networks: